TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00976326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
Study: NCT00369915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Study: NCT02907567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active study drug
Study: NCT04137328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
Study: NCT03183505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Study: NCT01383655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: i.v. magnesium 40mg/kg in 20 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl
Study: NCT01430468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenoid Positioning System
Description: Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
Study: NCT04484116

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative Paratohormone
Description: Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values \<150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative Paratohormone
Description: Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values \<150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
Study: NCT00974259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Management protocol based on pBrO2 and ICP values.
Description: For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (\> 20 mm Hg) or pBrO2 (\< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Management protocol based on ICP values only.
Description: For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
Study: NCT04508127

Intervention type: DEVICE
Intervention: Spinal cord stimulation
Study: NCT03202017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Muscle Strength Training (EMST)
Description: EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMST + Lung Volume Recruitment (LVR)
Description: EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique.
Study: NCT00354575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb: CCH1
Description: 1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Herb: CCH1
Description: 1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
Study: NCT03551327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention plus information
Description: The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.

Intervention type: OTHER
Group type: OTHER
Intervention: Active Comparator: Information only
Description: Participants in this arm will be provided with information about fatigue.
Study: NCT05629312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion
Description: The upper jaw is expanded with a removable expansion plate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of deciduous upper canines
Description: Both deciduous upper canines are extracted in this group
Study: NCT01425619

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cream of Macrogol cetostearyl ethers
Description: The cream will be applied on the volar aspect of both arms for 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %
Description: 1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care and treatment from a medical clown
Description: Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care and treatment from a medical clown
Description: Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
Study: NCT03794700

Intervention type: OTHER
Group type: OTHER
Intervention: Hospice Decision Aids
Description: Paper and video hospice decision aid
Study: NCT03532659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active video game
Description: Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
Study: NCT02120287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy (MRS)
Description: Subjects will have MRS prior to BZ-SRS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Border Zone Stereotactic Radiosurgery (BZ-SRS)
Description: The 'border zone' of the tumor will be targeted by SRS in a single session.
Study: NCT04314635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief family engagement intervention for CHR
Description: The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
Study: NCT01148329

Intervention type: DEVICE
Intervention: Coronary stenting
Description: The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
Study: NCT00872755

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen
Description: Laparoscopic Nissen Fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen
Description: Laparoscopic Nissen Fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastropexy
Description: posterior gastropexy
Study: NCT02519140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cook Medical EMR Gel
Description: Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
Study: NCT02310100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiCath Quartz treatment
Study: NCT01546532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030
Description: RLX030 as intravenous infusion for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of Placebo over 24 hours
Study: NCT01190059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion with Steen Solution™
Description: The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
Study: NCT03112824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha Root Extract Capsule
Description: Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Participants will take one placebo capsule orally twice a day for 12 weeks.
Study: NCT03339739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric mandibular exercises
Description: daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic mandibular exercises
Description: daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling group
Description: subjects included in this group get an education brochure about the disorder and receive no further interventions
Study: NCT01518153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein on Day -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein on Day -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 by vein on Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 by vein on Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 50 mg by vein on Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 50 mg by vein on Day -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Reduced intensity stem cell transplant on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Reduced intensity stem cell transplant on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Donor T-Cells
Description: Planned Donor Lymphocyte Infusion CD3+ cells: 3 \* 106 CD3+ cells/kg between Day +56 and +64.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Dose Donor T-Cells
Description: Planned Donor Lymphocyte Infusion CD3+ cells: 1 \* 107 CD3+ cells/kg between Day +56 and +64.
Study: NCT02327351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: TCR alfa beta T cell depletion
Study: NCT00229138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-MPS, Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-MPS, Tacrolimus
Study: NCT00743431

Intervention type: DRUG
Intervention: Caelyx (Pegylated Lyposomal Doxorubicin)
Description: Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
Study: NCT02473289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Description: Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo on Day 1, 28 and 56.
Study: NCT00613743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mouth wash with morphine
Description: morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
Study: NCT03211117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT02348944

Intervention type: OTHER
Intervention: serum and urine sample
Description: Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
Study: NCT02137317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAPPE (locally adapted personal protective equipment)
Description: * Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAPPE (locally adapted personal protective equipment)
Description: * Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes.
Study: NCT02481570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacokinetic simulation
Description: The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
Study: NCT03328104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: 650 mg/m2 IV daily x Day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 440 mg/m2 IV x Day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 IV x Day 1-5
Study: NCT03257527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCE group
Description: The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR group
Description: The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase.